SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Medicamen Biotech Ltd

BSE: 531146 NSE: MEDICAMEQ ISIN: INE646B01010
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Medicamen Biotech Ltd belong to?
Medicamen Biotech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Medicamen Biotech Ltd a good quality company?
Medicamen Biotech Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Medicamen Biotech Ltd undervalued or overvalued?
Medicamen Biotech Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Medicamen Biotech Ltd a good buy now?
Medicamen Biotech Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Medicamen Biotech Ltd?
Medicamen Biotech Ltd revenue growth is -12.1% for FY-2025 , which is below its 5 year CAGR of 5.2% , indicating slower growth.
Q.2 Gross Profit margin of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 13% for FY-2025 , which is below its 5 year median of 17.2% , indicating decreasing margins.
Q.3 Operating Profit Margin of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 11.29% for FY-2025 , which is below its 5 year median of 17.86% indicating decreasing margins.
Q.4 Net Profit Margin of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Net Profit Margin is 6.24% for FY-2025 , is below with its 5 year median of 10.88%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 13 17.2
Operating Profit Margin 11.29 17.86
Net Profit Margin 6.24 10.88
Q.5 Return on Asset of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Return on Asset is 3.25%, which is below its 5 year historical median of 6%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Return on equity is 4.57% for FY-2025 , which is below its historical median of 9.2%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Return on capital employed is 6.96% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Cash conversion cycle is 173 days, above its historical median of 118 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.52 0.55
ROE 4.57 9.2
ROCE 6.96 10.95
Cash Conversion Cycle 173 days 118 days
Q.9 Debt to Equity ratio of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Debt-to-Equity ratio is 0.13 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Medicamen Biotech Ltd?
Medicamen Biotech Ltd Debt to cash flow from operations is -10.4 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Medicamen Biotech Ltd?
Promoters hold 40.46% of the Medicamen Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Medicamen Biotech Ltd vs industry peers?
Medicamen Biotech Ltd revenue CAGR is 5.24% , compared to the industry median CAGR of 5.51% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 151.5 138.8
Gross Profit 19.6 16.2
Operating Profit 17 16
Net Profit 9 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.52 0.79
ROE 4.57 9.17
ROCE 6.96 11.78
Cash Conversion Cycle (days) 172.95 76

Valuation & price assessment

Q.1 Stock return of Medicamen Biotech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 12.4% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 12.4% -12.5% -28.8% -45.6%
Q.3 Valuation ratios of Medicamen Biotech Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 40.96 43.56 40.28
Price to Book 1.35 3.94 2.77
Price to Sales 2.41 4.30 2.65
EV to EBITDA 17.78 26.44 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Eris Lifesciences
10. Piramal Pharma
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×